anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Although considerable research has been conducted on post-COVID-19 syndrome (PCS), cognitive symptoms, particularly those related to language, are still not well understood.
AIMS: To provide a detailed quantitative and qualitative analysis of language performance in PCS patients using a comprehensive set of semantic and verbal production tasks.
METHODS & PROCEDURES: The study involved 195 PCS patients aged 26-64 years and 50 healthy controls aged 25-61 years. Participants were assessed using two semantic tasks, three naming tasks and four types of verbal fluency tasks, designed to evaluate different aspects of language processing.
OUTCOMES & RESULTS: PCS patients demonstrated significantly poorer performance compared with controls across all verbal fluency tasks. This was evident in both the total number of words generated and their types, with patients tending to choose more easily accessible words. In naming tasks, the pattern of errors was similar in both groups, although patients showed a higher number of non-responses and made more errors, reflecting difficulties in word retrieval. The analysis highlighted the impact of factors such as stimulus availability, educational level and cognitive reserve on performance. Notably, younger patients performed worse than older, a paradoxical trend also observed in previous research.
CONCLUSIONS & IMPLICATIONS: These findings reveal significant word retrieval difficulties in PCS patients, suggesting that cognitive impairment related to language may be more pronounced than previously understood. The results underscore the need for a thorough evaluation of language functions in PCS patients and the development of more targeted and individualized language rehabilitation strategies to address these specific challenges.
WHAT THIS PAPER ADDS: What is already known on the subject Studies on the cognitive characteristics of CPS have focused mainly on broad-spectrum neuropsychological assessments covering all cognitive functions. However, there are very few studies analysing oral production with specific lexical and semantic system tasks. Furthermore, no work has specifically included tasks assessing semantic processing or conducted qualitative analyses of the psycholinguistic variables affecting performance. Such analyses could undoubtedly help clarify the nature of the language impairments in patients with PCS. What this paper adds to the existing knowledge This study explores in depth the evaluation and analysis of the oral production of patients with PCS using several lexical and semantic tasks. In addition, psycholinguistic variables are analysed that could undoubtedly help clarify the nature of the language impairments in patients with PCS. What are the potential or actual clinical implications of this work? The study allows the identification of specific lexical-semantic deficits in the spoken language in patients with this PCS. A more detailed assessment of the oral language of these patients, keeping in mind the psycholinguistic variables that may affect the performance, will facilitate the design of more efficient and individualized rehabilitation programmes.
The present invention relates to a composition for enhancing immunity comprising prebiotics or synbiotics as an active ingredient. When the composition for enhancing immunity containing the prebiotics or synbiotics of the present invention as an active ingredient is fed to pigs, the composition may improve the clinical symptoms of porcine proliferative enteropathy (degree of mucosal thickening, defecation condition, etc.) and reduce the infection rate for the causative organism L. intracellularis strains. Furthermore, the composition for enhancing immunity of the present invention can promote the antibody production for foot-and-mouth disease vaccine. Therefore, the composition for enhancing immunity of the present invention can be advantageously used for treating porcine proliferative enteropathy and enhancing immunity of animals. Furthermore, when the composition for enhancing immunity of the present invention is administered to a human, the composition can contribute to increasing the efficacy of a vaccine in the human body.
PURPOSE:To obtain the solid cosmetic material contained in a container, in which a rather thin stripe pattern is formed extending from the upper face to the lower face by constituting it by filling closely the inside of an intermediate plate-like container with a plate-like cosmetic material punched body in which at least one side face is formed in a paint film layer of a different color. CONSTITUTION:A cosmetic material which consists of the same component as or a different component from a punched cosmetic material 3, and whose hue is different therefrom is formed like a viscous solution by mixing volatile alcohol such as isopropyl alcohol, etc., for exerting no influence on the skin and it is sprayed onto a side face part 3a of the punched cosmetic material from a spray B and dried. As a result, a sprayed paint film layer 4 of a different color is formed integrally on the side face part 3a of the punched cosmetic material 3 and a two-color cosmetic material 5 is obtained. The two-color cosmetic material 5 is combined with a cosmetic material 6 whose color is different from that of the cosmetic material 5 and placed in an intermediate plate 7. In this case, in accordance with necessity, it is executed to place thin paper 9 on the upper face of both the cosmetic materials 5, 6 and to press it by a press board 8. In such a way, gaps between the cosmetic material 5 and 6, and between both the cosmetic materials 5, 6 and the cosmetic material container 7 are filled up and the sprayed paint film layer 4 is formed in a rather thin stripe pattern.
AIM: Immunisation is a global health priority, but methods of non-pharmacological pain relief are not widely used in routine clinical practice. In this study, we set out to investigate the effects of maternal singing during the routine vaccination of infants.
METHODS: We recruited 67 mother-infant pairs at Health Centres in the Aosta Region of Italy. Infants aged 2-4 months were randomly allocated to a singing intervention group or to a control group whose injections were administered following standard practice. Pre- and post-immunisation pain was blindly assessed using the Modified Behavioural Pain Scale, and mother-infant proximity indexes were assigned based on muted video-tracks.
RESULTS: When assessed for pain, the infants in the maternal singing group were assigned significantly lower movement indexes (p = 0.032) and marginally significantly lower cry indexes (p = 0.076). A higher frequency of mother-to-infant gaze (p < 0.005) was observed in the singing group dyads. Finally, the intervention group mothers' self-perceived ease in singing was correlated with their previous singing experience and with lower anxiety following the vaccination procedure (p < 0.05).
CONCLUSION: Maternal singing during immunisation procedures benefits both mothers and babies. The practice of singing is a biologically rooted and adaptive form of intuitive parental communication that should be encouraged, especially in at-risk populations.
The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P 1 /S1P 3  activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P 3  expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P 3  and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results show that S1P is a very powerful role player in pharmacological marrow-derived stem cell mobilization and recruitment.
Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
Techniques are provided for detecting copy number variations. Each sequence read of a set of sequence reads is aligned with a portion of a reference sequence. A coverage vector is generated that includes a plurality of elements, each element in the plurality of elements indicating a number of the set of sequence reads that were aligned to a particular position within the reference sequence. A normalization vector is accessed that was generated based on performance of a component analysis on a set of other coverage vectors corresponding to a set of other subjects. An adjusted coverage vector is generated using the coverage vector and normalization vector. One or more subject-specific normalization values are generated based on the coverage vector. One or more copy number variations are identified that corresponding to the sample using the adjusted coverage vector and the subject-specific normalization values.
Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
PURPOSE: To obtain a new carcinostatic antibiotic sparoxomycin having high specificity against tumor cells and an action mechanism different from a conventional carcinostatic antibiotic. CONSTITUTION: This is an antibiotic expressed by formula I, that is, sparoxomycin A1 having an absolute configuration of formula II or sparoxomycin A2 having an absolute configuration of formula III. This antibiotic is obtained by culturing a microorganism belonging to the genus Streptomyces and producing an antibiotic sparoxomycin and collecting the antibiotic sparoxomycin from the cultured product. Anew streptomyces sp. SN-2325 (FERM P-14611) is suitably used as the actinomyces which produces the antibiotic sparoxomycin. The carcinostatic agent is effective against various kinds of carcinoma including a solid carcinoma such as gastric cancer, lung cancer, liver cancer, cancer of kidney, brain tumor, colon cancer and carcinoma of esophagus, malignant lymphoma, leukemia, etc.
A total of 100 people with recent injection drug use or recipients of opioid substitution therapy will be enrolled from drug and alcohol clinics, tertiary liver and infectious diseases clinics and community health centres across Canada, Europe, New Zealand, France, and Australia. This will include at least 30 participants with F3/F4 liver disease. Participants will be considered recent injection drug users if they have used injection drugs in the 6 months prior to consent. Participants receiving stable opioid substitution therapy (stable dose for \>2 weeks) will also be included. Patients with frequent drug use that is judged by the treating physician to compromise treatment safety will be excluded. The study drugs consisting of two tablets of the co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, ribavirin (1000 mg) daily in two divided doses (genotype 1a only and/or cirrhosis). Electronic blister packs will be used to improve and monitor treatment adherence. This innovative strategy with the "3D" interferon-free regimen could considerably enhance the capacity to scale-up HCV treatment among PWID, and is therefore being evaluated in this phase IV study within a well-defined PWID population.
The invention provides a method of transferring patient specific data (PSD) between a first location and a second location, and a corresponding system for doing the same. The first location may be on board an emergency medical services (EMS) vehicle and the second location may be a treatment site for the patient, such as a hospital. The method comprises collecting the patient specific data (PSD) from a patient in the first location with an electronic monitoring system (16) associated with a gas cylinder system (14) at the first location. The electronic monitoring system is further operable to monitor cylinder specific data (CSD) associated with the cylinder system. The patient specific data (PSD) is then transmitted from the electronic monitoring system (16), optionally along with the cylinder specific data (CSD), via an electronic communication channel (12) to a computer system (20) at the second location. Thus errors in transferring the patient specific data (PSD) from the first location to the second location which might otherwise from human error during a manual input of such data to the computer system (20) may be avoided. The PSD, and optionally the CSD, may be transmitted from the electronic monitoring system (16) to the computer system (20) in one of several ways. Thus the electronic communication channel (12) may comprise a high-powered transceiver, a cloud computing system and/or a handheld electronic device operating a wireless near-field communication protocol, for example.
Disclosed is a laminated sheet which is composed of non-woven fiber assemblies. The laminated sheet comprises: a liquid-retaining layer which can absorb a liquid component; and an adhesive layer which is formed on at least one surface of the liquid-retaining layer and can be penetrated with the liquid component and with which the skin is to be contacted. The adhesive layer comprises non-woven fiber assemblies having a number average fiber diameter of 10 μm or less, and the ratio of the thickness of the adhesive layer to the thickness of the liquid-retaining layer (i.e., an (adhesive layer)/(liquid-retaining layer) ratio) of 1/4 to 1/100. The adhesive layer may be composed of non-woven fiber assemblies in which the standard deviation of the fiber diameters is 5 or less. The liquid-retaining layer may be composed of non-woven fabric fiber assemblies having larger fiber diameters than those of the fibers that constitute the adhesive layer. The laminated sheet has an excellent balance between liquid-retaining properties and liquid-releasing properties, and also has excellent adhesiveness and fitting properties to the skin when the laminated sheet is impregnated with a liquid component.
OBJECTIVES: I. Compare the median survival of patients with glioblastoma multiforme in first relapse treated with intravenous leflunomide (SU101) administered as a loading dose with weekly maintenance therapy versus oral, single-agent procarbazine administered daily for 28 days every 56 days. II. Compare the median time to progression for these regimens in these patients. III. Assess the objective response of these patients. IV. Assess the safety of SU101 given on this schedule. V. Describe the health-related quality of life of these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to performance status (Karnofsky 60-80% vs 90-100%), age (less than 50 vs 50 and over), and time from initial diagnosis to recurrence (6 months or greater vs less than 6 months). Patients are randomized to one of two treatment arms. Arm I: Patients receive leflunomide (SU101) IV over 6 hours daily on days 1-4, again 4-8 days later, and weekly thereafter for a total of 4 loading dose infusions and six maintenance infusions in course 1. Patients receive 7 weekly maintenance infusions of SU101 in courses thereafter. Treatment repeats every 8 weeks. Arm II: Patients receive procarbazine orally once or twice daily for 4 weeks. Treatment is repeated every 8 weeks. All patients complete a health-related quality-of-life questionnaire every 8 weeks and at study withdrawal. Treatment courses continue up to a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients are followed every 2 months, beginning 30 days after study completion.

PROJECTED ACCRUAL: A maximum of 380 patients will be accrued for this study.
Influenza infection is associated with a risk of thrombosis. Whether factors associated with reduced thrombosis might also be associated with reduced risk in patients with severe influenza is unknown. To investigate risk factors associated with thrombosis in patients with severe influenza. We used a cohort data set to identify adults diagnosed with severe influenza. Univariable and multivariable logistic regression models explored potential risk factors for thrombosis events in patients with severe influenza. Cox regression analysis was used to examine the risk factors for mortality in patients with severe influenza. A total of 854 patients with severe influenza were included in the analysis. The incidence of VTE was 9.37% (80/854). Multivariable regression analysis showed that previous aspirin medication (OR: 0.37; 95%CI: 0.14-0.84; P = .029) could reduce the risk factor of thrombosis in patients with severe influenza. Compared with patients in the non-thrombosis group, patients in the thrombosis group required more mechanical ventilation (P < .001), tracheostomy (P < .001), ECMO (P = .046), and high-frequency ventilation (P = .004). The incidence of co-infection was higher in the thrombosis group compared to the non-thrombosis group (P = .025). Univariable Cox regression analysis showed that previous aspirin medication (HR 0.52, 95%CI: 0.33-0.82, P = .005) and previous statin medication (HR 0.54, 95%CI: 0.34-0.87, P = .011) were risk factors for 60-day mortality in patients with severe influenza. Patients with severe influenza are at high risk for thrombosis. The effect of aspirin on thrombosis in patients with severe influenza needs further investigation.
The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. The application of IE is expected to reduce the threat value of pain and subsequently promote recovery. This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks. Depending on the length of baseline (i.e. observation period before the start of intervention) the study will last between 6 and 8 weeks. Daily Diary, a short nine item instrument was designed to measure the pain experience (intensity and interference) and fear of pain on a daily basis. Other, standard outcome measures include: pain related anxiety, pain catastrophising, pain related disability, knowledge about pain and general anxiety and depression. Study participants will be recruited during routine psychology screening assessment at the Pain Clinic at St James' Hospital. This study will recruit from clinical psychology waiting list patients.
The purpose of the present invention is to provide a traditional Chinese medicine for treatment of myopia with good effects. The technical solution is that: the traditional Chinese medicine for treatment of myopia includes the components of: Chinese foxglove root, glossy privet fruit, mulberry, medlar, dogwood, concha haliotidis, motherwort fruit, dodder seed, plantago seeds, schisandra chinensis, processed fleece flower root, codonopsis root, poria cocos, rhizoma acori graminei, polygala tenuifolia, astragalus mongholicus, angelica, radix ophiopogonis, and asparagus cochinchinensis. The above medicines are added into water of 2-3 times of total weight of the medicines, then soaked, boiled by big fire, decocted for 20-30 minutes by small fire, and filtered to remove residues to get a soup. The residues are then boiled and decocted for a second time, and then filtered to remove the residues to get a soup. The soups are mixed and the preparation is complete. The present invention is low in production costs, quick in effects, has a good effect on treatment of myopia, has a wide use crowd, and can effectively relieve and treat myopia symptoms.
The present invention relates to a pharmaceutical composition and a health food which include a mixed medicinal herb extract derived from natural plants as an active ingredient for the prevention or treatment of cancer. More specifically, the present invention relates to a pharmaceutical composition and a health food which include an extract of a medicinal herb mixture as an active ingredient for the prevention or treatment of cancer, wherein the medicinal herb mixture comprises Cnidii Rhizoma, Ledebouriella seseloides WOLFF., Angelicae Gigantis Radix, Paeonia lactiflora Pall., Forsythia Viridissima Lindley, Mentha arvensis var. piperascens, Ephedra sinica, Erigeron canadensis, Rheum palmatum L., Gypsum fibrosum, Platycodon grandiflorum A. De Candolle, Scutellaria baicalensis GEORGE, Atractylodes macrocephala Koidzumi, Gardenia jasminoides, Schizonepeta rhizome, Zingiberis Rhizoma, talc, Glycyrrhiza uralensis Fischer, Lonicera japonica Thunberg, Epimedium koreanum Nakai, Polygala tenuifolia and elecampane. According to the present invention, the mixed medicinal herb extract has activities of effectively inhibiting metastasis, inducing apoptosis and inhibiting cell growth against cancer cells. Therefore, the mixed medicinal herb extract can be pharmaceutically used for a composition for the prevention or treatment of cancer and also can be practically used for a health food.
Group 2 will be treated with the usual rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session, exactly as Group 1. Additionally, the children will receive daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
Administer ASMANEX HFA only by the orally inhaled route [see Instructions for Use in the Patient Information leaflet]. After each dose, advise patients to rinse their mouth with water and, without swallowing, spit out the contents to help reduce the risk of oropharyngeal candidiasis.

Remove the cap from the mouthpiece of the actuator before using ASMANEX HFA.

Prime ASMANEX HFA before using for the first time by releasing 4 test sprays into the air, away from the face, shaking well before each spray. In cases where the inhaler has not been used for more than 5 days, prime the inhaler again by releasing 4 test sprays into the air, away from the face, shaking well before each spray.

Only use the ASMANEX HFA canister with the ASMANEX HFA actuator. Do not use the ASMANEX HFA actuator with any other inhalation drug product. Do not use actuators from other products with the ASMANEX HFA canister.